Larotrectinib (Vitrakvi)

Ingredients: Larotrectinib
Dosage Form: Capsules
Innovator’s Brand Name: Vitrakvi
Generic Brand Name: Tractoni
Generic Manufacturer: Ziska Pharma

Indications:
Larotrectinib is a targeted anti‑cancer medication against neurotrophic tyrosine receptor kinase (NTRK) gene fusions. It is the first approved tumor‑agnostic oral TRK inhibitor, indicated for the treatment of patients with solid tumors harboring an NTRK gene fusion, regardless of tumor origin.

Dosage and Administration:
For patients with a body surface area ≥ 1 m², the recommended dose is 100 mg orally twice daily. For patients with a body surface area < 1 m², the dose is 100 mg/m² orally twice daily. Swallow capsules whole; if a dose is missed, skip it—do not double the next dose.

Adverse Reactions:
Common adverse reactions include neurotoxicity and hepatotoxicity.

Storage:
Store in a cool, dry place below 30 °C, protected from direct sunlight, and keep out of reach of children.

Package Insert (Prescribing Information):

Download Link